Statement: Two different types of tachycardia occurred to patients in cohort 2 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 32/106 (30.19%)   Febrile neutropenia * 6/106 (5.66%)   Leukopenia * 1/106 (0.94%)   Neutropenia * 1/106 (0.94%)   Arrhythmia * 1/106 (0.94%)   Atrial fibrillation * 0/106 (0.00%)   Cardiac failure * 0/106 (0.00%)   Left ventricular dysfunction * 1/106 (0.94%)   Myocardial infarction * 1/106 (0.94%)   Supraventricular tachycardia * 0/106 (0.00%)   Tachycardia * 0/106 (0.00%) Adverse Events 2:   Total: 44/107 (41.12%)   Febrile neutropenia * 3/107 (2.80%)   Leukopenia * 0/107 (0.00%)   Neutropenia * 3/107 (2.80%)   Arrhythmia * 0/107 (0.00%)   Atrial fibrillation * 1/107 (0.93%)   Cardiac failure * 1/107 (0.93%)   Left ventricular dysfunction * 0/107 (0.00%)   Myocardial infarction * 0/107 (0.00%)   Supraventricular tachycardia * 1/107 (0.93%)   Tachycardia * 1/107 (0.93%)